TY - CHAP
T1 - Circulating MicroRNAs as noninvasive biomarkers in breast cancer
AU - Cortez, Maria Angelica
AU - Welsh, James William
AU - Calin, George Adrian
N1 - Funding Information:
G.A.C. is supported as a fellow by The University of Texas MD Anderson Research Trust, as a University of Texas System Regents research scholar, and by the CLL Global Research Foundation. Work in Dr. Calin’s laboratory is supported in part by the National Institutes of Health; a Department of Defense Breast Cancer Idea Award; Developmental Research Awards in Breast Cancer; MD Anderson’s Ovarian Cancer, Brain Cancer, and Leukemia SPORE grants; a CTT/3I-TD grant; a 2009 Seena Magowitz—Pancreatic Cancer Action Network AACR Pilot Grant; and MD Anderson’s Cancer Center Support Grant CA016672. J.W.Welsh is supported in part by Paul Calabreski K-12 grant. We thank Ann Sutton for her help in editing this manuscript.
PY - 2012
Y1 - 2012
N2 - MicroRNAs (miRNAs) are master regulators of gene expression. By degrading or blocking translation of messenger RNA targets, these non-coding RNAs can modulate the expression of more than half the protein-coding genes in mammalian genomes. MiRNAs play important regulatory roles in a variety of cellular functions and in several diseases, including cancer. Aberrant miRNA expression has been well characterized in cancer, with implications for progression and prognosis. Recently, the discovery of miRNAs in body fluids, such as serum and plasma, opens up the possibility of using them as noninvasive biomarkers of disease and therapy response. In this chapter, we discuss the use of circulating miRNAs as biomarkers of disease and therapy response and as diagnostic and prognostic markers in breast cancer. We also discuss the main issues related to establishing circulating miRNAs as biomarkers in cancer.
AB - MicroRNAs (miRNAs) are master regulators of gene expression. By degrading or blocking translation of messenger RNA targets, these non-coding RNAs can modulate the expression of more than half the protein-coding genes in mammalian genomes. MiRNAs play important regulatory roles in a variety of cellular functions and in several diseases, including cancer. Aberrant miRNA expression has been well characterized in cancer, with implications for progression and prognosis. Recently, the discovery of miRNAs in body fluids, such as serum and plasma, opens up the possibility of using them as noninvasive biomarkers of disease and therapy response. In this chapter, we discuss the use of circulating miRNAs as biomarkers of disease and therapy response and as diagnostic and prognostic markers in breast cancer. We also discuss the main issues related to establishing circulating miRNAs as biomarkers in cancer.
UR - http://www.scopus.com/inward/record.url?scp=84860577261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860577261&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-28160-0_13
DO - 10.1007/978-3-642-28160-0_13
M3 - Chapter
C2 - 22527502
AN - SCOPUS:84860577261
SN - 9783642281594
T3 - Recent Results in Cancer Research
SP - 151
EP - 161
BT - Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
A2 - Ignatiadis, Michail
A2 - Sotiriou, Christos
A2 - Pantel, Klaus
ER -